6 South Street
About Cingulate TherapeuticsCingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
Dec. 1, 2012
Founder and CEO: Shane J. Schaffer
Founder and CSO: Raul R. Silva
Founder and CFO: Craig S. Tashjy
11 articles with Cingulate Therapeutics
Cingulate Therapeutics LLC announced that Shane J. Schaffer, PharmD, Chairman and CEO of Cingulate Therapeutics, will present at Biotech Showcase 2019 to be held January 6-9, 2019, at the Hilton San Francisco Union Square
Industry veteran Peter J. Werth to join Cingulate Therapeutics Board of Directors
Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Jeff Conroy and Jeff Hargroves to its Board of Directors
Dr. Myers currently serves as a founding member of the Cingulate Therapeutics Board of Directors.
Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
Overall, researchers found that CTX-1301 delivered consistent tri-modal release of the dexmethylphenidate hydrochloride.
Dr. Brams is a Co-Founder of Cingulate Therapeutics and currently serves as a member of the Board of Directors.
Cingulate Therapeutics to Present in Vivo Pharmacokinetic Data Demonstrating Consistent Tri-Phasic Release Profile of Lead Compound at the AAPS Annual Meeting
The study evaluated CTX-1301, Cingulate's proprietary, first-line stimulant medication for the treatment of ADHD, utilizing an innovative, proprietary timed release technology OralogiK developed by CTx's partner BDD.